ExCellThera_RGB.png
ExCellThera receives FDA orphan drug designation for ECT-001 for the prevention of graft-versus-host disease
December 17, 2018 08:05 ET | ExCellThera
MONTREAL, Dec. 17, 2018 (GLOBE NEWSWIRE) -- ExCellThera Inc., a biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced...
ExCellThera_RGB.png
ExCellThera announces results of clinical trial using ECT-001 for blood cancers
December 04, 2018 07:05 ET | ExCellThera
MONTREAL, Dec. 04, 2018 (GLOBE NEWSWIRE) -- ExCellThera Inc., a biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, today...
ExCellThera_RGB.png
ExCellThera announces clinical trial results using ECT-001 to be presented at ASH 2018 annual meeting
November 08, 2018 07:05 ET | ExCellThera
MONTREAL, Nov. 08, 2018 (GLOBE NEWSWIRE) -- ExCellThera Inc., a biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, today...
Final patient receives treatment in stem cell clinical trial for severe blood cancers
June 27, 2018 08:50 ET | ExCellThera
MONTREAL, June 27, 2018 (GLOBE NEWSWIRE) -- ExCellThera Inc., a biotechnology company delivering molecules and bioengineering solutions to expand blood stem cells for therapeutic use, announced...